First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.

Yohann Loriot; Petros Grivas; Ronald De Wit; Arjun Vasant Balar; Arlene O. Siefker-Radtke; Jakub Zolnierek; Tibor Csoszi; Sang Joon Shin; Se Hoon Park; Vagif Atduev; Mahmut Gumus; Yu-Li Su; Saziye Burcak Karaca; Hernan Cutuli; Mehmet Nahit Sendur; Calvin Jia; Karen O'Hara; Sonia Franco; Nobuaki Matsubara

doi:10.1200/JCO.2022.40.6_suppl.432

YUHSpace

BROWSE

0 294

Cited 0 times in

First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.

Authors: Yohann Loriot ; Petros Grivas ; Ronald De Wit ; Arjun Vasant Balar ; Arlene O. Siefker-Radtke ; Jakub Zolnierek ; Tibor Csoszi ; Sang Joon Shin ; Se Hoon Park ; Vagif Atduev ; Mahmut Gumus ; Yu-Li Su ; Saziye Burcak Karaca ; Hernan Cutuli ; Mehmet Nahit Sendur ; Calvin Jia ; Karen O'Hara ; Sonia Franco ; Nobuaki Matsubara